Unmatched Quality Standards
Pioneering Life-Saving
Pharmaceuticals
No. 1 Among Inhalation Drug Manufacturers
Leader in Asthma
and COPD Treatment
and COPD Treatment
Since 2021, PSK Pharma has held the leading position in the number of pulmonary drugs in its portfolio, with 23 active pharmaceutical ingredients recognized as the "gold standard" in asthma and COPD therapy. The efficacy and safety of our inhalation medications are validated by clinical trial results.
Full-cycle
MANUFACTURING at SEZ Dubna
MANUFACTURING at SEZ Dubna
PSK Pharma is a proud member of our corporate group
MAIN AREAS OF PRODUCTION:
Genetically engineered biotechnological products
Comprehensive portfolio for the treatment of Asthma and COPD
Targeted therapies for severe and rare diseases
Breathe easy
THE BREATHE EASY SOCIAL INITIATIVE
The «Breathe Easy» initiative is dedicated to supporting patients with respiratory conditions, including asthma and COPD, in achieving a better quality of life.
This initiative provides comprehensive patient support, from accurate diagnosis to expert treatment consultation, and plays a crucial role in the prevention and management of respiratory diseases
Pharmacovigilance
COMMITMENT TO DRUG QUALITY
Our company is dedicated to ongoing safety surveillance, facilitating the identification of adverse reactions in patients and the prompt dissemination of current and updated information to healthcare professionals and patients about our medications.
Should you experience any adverse reactions while using "PSK Pharma" products or have concerns regarding their quality, please contact us through any preferred channel to report your experience.
Should you experience any adverse reactions while using "PSK Pharma" products or have concerns regarding their quality, please contact us through any preferred channel to report your experience.
PSK Pharma —
Leading Domestic Pharmaceutical Manufacturer
Leading Domestic Pharmaceutical Manufacturer
Eighty percent of our products are on the Essential Medicines List (EML), while the remaining are supplementary. Our portfolio includes treatments for asthma and COPD, rheumatoid arthritis, HIV, tuberculosis, rare diseases, neurological and gastrointestinal disorders, as well as antifungal and anti-infective drugs, and antibiotics. These medications are employed in oncohematology, cardiology, anesthesiology, and critical care. Our primary focus is on developing biotechnological products to meet modern healthcare needs.